HRP20250864T1 - Kristalni oblici p2x3 modulatora metil (s)‑2‑((2‑(2,6‑difluoro‑4‑(metilkarbamoil)fenil)‑7‑metilimidazo[1,2‑a] piridin‑3‑il)metil)morfolin‑4‑karboksilata - Google Patents
Kristalni oblici p2x3 modulatora metil (s)‑2‑((2‑(2,6‑difluoro‑4‑(metilkarbamoil)fenil)‑7‑metilimidazo[1,2‑a] piridin‑3‑il)metil)morfolin‑4‑karboksilataInfo
- Publication number
- HRP20250864T1 HRP20250864T1 HRP20250864TT HRP20250864T HRP20250864T1 HR P20250864 T1 HRP20250864 T1 HR P20250864T1 HR P20250864T T HRP20250864T T HR P20250864TT HR P20250864 T HRP20250864 T HR P20250864T HR P20250864 T1 HRP20250864 T1 HR P20250864T1
- Authority
- HR
- Croatia
- Prior art keywords
- crystalline form
- theta
- methyl
- type
- form according
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862760307P | 2018-11-13 | 2018-11-13 | |
| EP19884611.5A EP3880678B1 (en) | 2018-11-13 | 2019-11-12 | Crystalline forms of p2x3 modulator methyl (s)-2-((2-(2,6-difluoro-4-(methylcarbamoyl )phenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate |
| PCT/IB2019/001199 WO2020099923A1 (en) | 2018-11-13 | 2019-11-12 | Crystalline forms of a substituted imidazopyridine compound and use thereof as p2x3 modulator |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20250864T1 true HRP20250864T1 (hr) | 2025-09-26 |
Family
ID=70732059
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20250864TT HRP20250864T1 (hr) | 2018-11-13 | 2019-11-12 | Kristalni oblici p2x3 modulatora metil (s)‑2‑((2‑(2,6‑difluoro‑4‑(metilkarbamoil)fenil)‑7‑metilimidazo[1,2‑a] piridin‑3‑il)metil)morfolin‑4‑karboksilata |
Country Status (20)
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL282087B2 (en) * | 2018-10-10 | 2025-11-01 | Bellus Health Cough Inc | 4-(imidazo[1,2-a]pyridin-3-yl)-benzamide derivatives for treating pruritus |
| DK3880678T3 (da) | 2018-11-13 | 2025-06-10 | Glaxosmithkline Intellectual Property No 3 Ltd | Krystallinske former af p2x3-modulator methyl(s)-2-((2-(2,6-difluoro-4-(methylcarbamoyl )phenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholin-4-carboxylat |
| CA3131312A1 (en) | 2019-02-25 | 2020-09-03 | Bellus Health Cough Inc. | Treatment with p2x3 modulators |
| CN114085220B (zh) * | 2020-06-22 | 2023-06-16 | 上海海雁医药科技有限公司 | 取代的吗啉-4-羧酸酯衍生物、其组合物及医药上的用途 |
| WO2022001820A1 (zh) * | 2020-06-29 | 2022-01-06 | 武汉朗来科技发展有限公司 | 杂环类化合物的晶型及其制备方法和应用 |
| WO2022161462A1 (zh) * | 2021-01-29 | 2022-08-04 | 上海海雁医药科技有限公司 | 吗啉衍生物及其药物组合物和用途 |
| AU2024410803A1 (en) * | 2023-12-29 | 2026-07-02 | Hubei Bio-Pharmaceutical Industrial Technological Institute Inc. | Solid dispersion of p2x3 receptor antagonist and preparation process thereof |
| WO2025191081A1 (en) | 2024-03-15 | 2025-09-18 | Glaxosmithkline Intellectual Property (No.3) Limited | Crystalline form of camlipixant |
| WO2025210540A1 (en) | 2024-04-02 | 2025-10-09 | Assia Chemical Industries Ltd. | Solid state forms of camlipixant and process for preparation thereof |
| WO2026022326A1 (en) * | 2024-07-25 | 2026-01-29 | Glaxosmithkline Intellectual Property (No.3) Limited | P2x3 antagonist formulation |
| JP2026049185A (ja) | 2024-09-06 | 2026-03-18 | キヤノン株式会社 | 撮像装置、撮像方法、及びコンピュータプログラム |
| WO2026078642A1 (en) * | 2024-10-11 | 2026-04-16 | Apitoria Pharma Private Limited | Novel crystalline form of camlipixant and process for the preparation thereof |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH503559A (de) | 1969-02-26 | 1971-02-28 | Arx Paul Von | Vorrichtung an Tafelschere zum Schneiden nach Markierungen, unter ständiger Beobachtung des Schnittes |
| GB9119920D0 (en) | 1991-09-18 | 1991-10-30 | Glaxo Group Ltd | Chemical compounds |
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| CA2242425C (en) | 1996-02-13 | 2006-07-18 | Zeneca Limited | Quinazoline derivatives as vegf inhibitors |
| NZ331191A (en) | 1996-03-05 | 2000-03-27 | Zeneca Ltd | 4-anilinoquinazoline derivatives and pharmaceutical compositions thereof |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
| GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
| GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
| EE05345B1 (et) | 1999-02-10 | 2010-10-15 | Astrazeneca Ab | Kinasoliini derivaadid angiogeneesi inhibiitoritena |
| US6673908B1 (en) * | 1999-02-22 | 2004-01-06 | Nuvelo, Inc. | Tumor necrosis factor receptor 2 |
| BR0111230A (pt) | 2000-05-31 | 2003-06-10 | Astrazeneca Ab | Composto, e, uso e processo para a preparação do mesmo |
| UA73993C2 (uk) | 2000-06-06 | 2005-10-17 | Астразенека Аб | Хіназолінові похідні для лікування пухлин та фармацевтична композиція |
| KR20030014425A (ko) | 2000-07-07 | 2003-02-17 | 앤지오젠 파마슈티칼스 리미티드 | 혈관 손상제인 콜치놀 유도체 |
| EE200300015A (et) | 2000-07-07 | 2004-10-15 | Angiogene Pharmaceuticals Limited | Kolhinooli derivaadid kui angiogeneesi inhibiitorid |
| AU2002305236A1 (en) | 2001-04-24 | 2002-11-05 | Epigenesis Pharmaceuticals, Inc. | Composition, formulations and kits for treatment of respiratory and lung disease with anti-sense oligonucleotides and a bronchodilating agent |
| WO2003014732A1 (en) * | 2001-08-10 | 2003-02-20 | Symyx Technologies, Inc. | Apparatuses and methods for creating and testing pre-formulations and systems for same |
| SE0102808D0 (sv) | 2001-08-22 | 2001-08-22 | Astrazeneca Ab | New compounds |
| JP2004002826A (ja) | 2002-04-24 | 2004-01-08 | Sankyo Co Ltd | 高分子イミダゾピリジン誘導体 |
| BRPI0515897A (pt) | 2004-09-24 | 2008-08-12 | Astrazeneca Ab | composto, uso do mesmo, composição farmacêutica, e, método para a terapia de dor em um animal de sangue quente, e para a preparação de um composto |
| JP5198256B2 (ja) | 2005-05-04 | 2013-05-15 | エボテク エージー | 縮合複素環式化合物、並びにそれらの組成物及び使用 |
| DE102006028862A1 (de) | 2006-06-23 | 2007-12-27 | Merck Patent Gmbh | 3-Amino-imidazo[1,2-a]pyridinderivate |
| US20090099195A1 (en) | 2007-05-08 | 2009-04-16 | Astrazeneca Ab | Therapeutic Compounds 570 |
| US20110237578A1 (en) | 2008-09-18 | 2011-09-29 | Zhi-Liang Wei | Amide compounds, compositions and uses thereof |
| ES2442797T3 (es) | 2009-11-18 | 2014-02-13 | Neomed Institute | Compuestos de benzoimidazol y sus utilizaciones |
| WO2013002584A2 (ko) | 2011-06-28 | 2013-01-03 | 주식회사 비보존 | 다중 타겟팅의 상승 효과를 유발하는 유효물질의 조합 및 그 용도 |
| KR102120513B1 (ko) | 2013-01-31 | 2020-06-08 | 네오메드 인스티튜트 | 이미다조피리딘 화합물 및 이의 용도 |
| BR112016003157B1 (pt) | 2013-08-15 | 2021-07-13 | Volvo Truck Corporation | Método e disposição para balanceamento de um sistema de armazenamento de energia |
| PE20160431A1 (es) | 2013-08-23 | 2016-06-02 | Afferent Pharmaceuticals Inc | Moduladores del receptor p2x3 y p2x2/3 de diaminopiridina para el tratamiento de la tos aguda, sub-aguda o cronica |
| CU24411B1 (es) | 2014-12-09 | 2019-05-03 | Bayer Ag | Compuesto derivado de benzamida sustituida con 1,3-tiazol-2-ilo útil para el tratamiento de trastornos neurogénicos |
| CA2998742C (en) | 2015-09-29 | 2023-08-29 | Anthony P. FORD | Diaminopyrimidine p2x3 and p2x2/3 receptor modulators for use in the treatment of cough |
| US9907795B2 (en) | 2016-01-08 | 2018-03-06 | Nerre Therapeutics Limited | Method of treatment of chronic cough administering orvepitant in combination with other therapeutic agents |
| US10822311B2 (en) | 2016-03-14 | 2020-11-03 | Afferent Pharmaceuticals, Inc. | Pyrimidines and variants thereof, and uses therefor |
| CN109462996A (zh) | 2016-03-17 | 2019-03-12 | 西达-赛奈医疗中心 | 通过rnaset2诊断炎性肠病的方法 |
| CN109996546B (zh) | 2016-09-30 | 2023-06-27 | 阿沙纳生物科学公司 | P2x3和/或p2x2/3化合物及方法 |
| US10111883B1 (en) * | 2017-09-18 | 2018-10-30 | Bellus Health Cough Inc. | Selective P2X3 modulators |
| IL282087B2 (en) | 2018-10-10 | 2025-11-01 | Bellus Health Cough Inc | 4-(imidazo[1,2-a]pyridin-3-yl)-benzamide derivatives for treating pruritus |
| DK3880678T3 (da) | 2018-11-13 | 2025-06-10 | Glaxosmithkline Intellectual Property No 3 Ltd | Krystallinske former af p2x3-modulator methyl(s)-2-((2-(2,6-difluoro-4-(methylcarbamoyl )phenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholin-4-carboxylat |
| WO2020112890A1 (en) | 2018-11-29 | 2020-06-04 | Cedars-Sinai Medical Center | Rnaset2 compositions and methods of treatment therewith |
| KR102797127B1 (ko) | 2018-12-29 | 2025-04-21 | 우한 크리에이터나 사이언스 앤드 테크놀로지 컴퍼니, 리미티드 | 헤테로고리계 화합물, 중간체, 이의 제조 방법 및 용도 |
| CA3131312A1 (en) | 2019-02-25 | 2020-09-03 | Bellus Health Cough Inc. | Treatment with p2x3 modulators |
| JP2023513373A (ja) | 2020-02-14 | 2023-03-30 | べルス・ヘルス・コフ・インコーポレーテッド | P2x3修飾薬 |
| BR112022015818A2 (pt) | 2020-02-14 | 2022-10-25 | Bellus Health Cough Inc | Preparação de um antagonista de p2x3 |
-
2019
- 2019-11-12 DK DK19884611.5T patent/DK3880678T3/da active
- 2019-11-12 HR HRP20250864TT patent/HRP20250864T1/hr unknown
- 2019-11-12 LT LTEPPCT/IB2019/001199T patent/LT3880678T/lt unknown
- 2019-11-12 MX MX2021005424A patent/MX2021005424A/es unknown
- 2019-11-12 SM SM20250237T patent/SMT202500237T1/it unknown
- 2019-11-12 CA CA3119711A patent/CA3119711A1/en active Pending
- 2019-11-12 WO PCT/IB2019/001199 patent/WO2020099923A1/en not_active Ceased
- 2019-11-12 EP EP19884611.5A patent/EP3880678B1/en active Active
- 2019-11-12 HU HUE19884611A patent/HUE071480T2/hu unknown
- 2019-11-12 FI FIEP19884611.5T patent/FI3880678T3/fi active
- 2019-11-12 PT PT198846115T patent/PT3880678T/pt unknown
- 2019-11-12 PL PL19884611.5T patent/PL3880678T3/pl unknown
- 2019-11-12 RS RS20250594A patent/RS66922B1/sr unknown
- 2019-11-12 JP JP2021525726A patent/JP2022507251A/ja active Pending
- 2019-11-12 CN CN201980088914.9A patent/CN113302191A/zh active Pending
- 2019-11-12 AU AU2019378161A patent/AU2019378161B2/en active Active
- 2019-11-12 ES ES19884611T patent/ES3033466T3/es active Active
- 2019-11-12 US US17/292,663 patent/US12637452B2/en active Active
- 2019-11-12 SI SI201930943T patent/SI3880678T1/sl unknown
-
2021
- 2021-05-06 IL IL282996A patent/IL282996A/en unknown
-
2024
- 2024-07-05 JP JP2024109053A patent/JP2024153665A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3880678B1 (en) | 2025-05-07 |
| ES3033466T3 (en) | 2025-08-04 |
| MX2021005424A (es) | 2021-06-15 |
| HUE071480T2 (hu) | 2025-08-28 |
| CA3119711A1 (en) | 2020-05-22 |
| IL282996A (en) | 2021-06-30 |
| EP3880678A4 (en) | 2022-08-31 |
| DK3880678T3 (da) | 2025-06-10 |
| JP2022507251A (ja) | 2022-01-18 |
| US12637452B2 (en) | 2026-05-26 |
| SI3880678T1 (sl) | 2025-08-29 |
| PT3880678T (pt) | 2025-05-22 |
| US20220002292A1 (en) | 2022-01-06 |
| SMT202500237T1 (it) | 2025-07-22 |
| LT3880678T (lt) | 2025-06-25 |
| EP3880678A1 (en) | 2021-09-22 |
| WO2020099923A1 (en) | 2020-05-22 |
| PL3880678T3 (pl) | 2025-08-04 |
| AU2019378161B2 (en) | 2025-01-30 |
| FI3880678T3 (fi) | 2025-08-01 |
| JP2024153665A (ja) | 2024-10-29 |
| CN113302191A (zh) | 2021-08-24 |
| RS66922B1 (sr) | 2025-07-31 |
| AU2019378161A1 (en) | 2021-06-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI3880678T3 (fi) | P2x3-muuntaja metyyli-(s)-2-((2-(2,6-difluori-4-(metyylikarbamoyyli)fenyyli)-7-metyyli-imidatso[1,2-a]pyridin-3-yyli)metyyli)morfoliini-4-karboksylaatin kidemuotoja | |
| JP2022507251A5 (cg-RX-API-DMAC7.html) | ||
| HRP20180970T1 (hr) | Policiklični lpa1 antagonist i njegove primjene | |
| IL291099B1 (en) | Aminothiazole compounds as C–KIT inhibitors | |
| HRP20240304T1 (hr) | Soli valbenazin dihidroklorida i njihovi polimorfi | |
| HRP20210252T1 (hr) | Heterociklički amidi kao inhibitori kinaze | |
| HRP20200280T1 (hr) | Derivati 1,3,4-oksadiazolsulfamida kao inhibitor histonske deacetilaze 6 i farmaceutski pripravak koji ih sadrži | |
| JP2013525433A5 (cg-RX-API-DMAC7.html) | ||
| GB2571950A8 (en) | New polymorph and new path to synthesize tafamidis | |
| SI3102573T1 (en) | SUBSTITUTED TIAZOL OR OXASOL AS ANTAGONISTS OF THE RECEPTOR P2X7 | |
| JP2014520108A5 (cg-RX-API-DMAC7.html) | ||
| HRP20140611T1 (hr) | Inhibitori kinaze p70 s6 | |
| CN111655678A (zh) | 细胞凋亡信号调节激酶-1抑制剂及其应用 | |
| JP2020508327A5 (cg-RX-API-DMAC7.html) | ||
| ME03800B (me) | Heteroaril amidi kao inhibitori proteinske agregacije | |
| AR106612A1 (es) | Sales, formas cristalinas y composiciones farmacéuticas de 4-[2-(4-amino-piperidin-1-il)-5-(3-fluoro-4-metoxi-fenil)-1-metil-6-oxo-1,6-dihidro-pirimidin-4-il]-2-fluorobenzonitrilo como inhibidor de demetilasa 1 específica de lisina | |
| HRP20201644T1 (hr) | Kristalni oblik 2-butoksi-7-(4-(pirolidin-1-ilmetil)benzil)-5h-pirolo [3,2-d]pirimidin-4-amina kao agonist tlr7, postupak njegove proizvodnje i njegova uporaba | |
| DK2966079T1 (da) | Pyridopyrimidin eller pyrimidopyrimidinforbindelse, fremstillingsmetode, pharmaceutisk præparat og anvendelse heraf | |
| JP2011500621A5 (cg-RX-API-DMAC7.html) | ||
| ME02672B (me) | Fenil-3-aza-bicikl0[3.1.0]heks-3-il-metanoni i njihova primena kao medikament | |
| JP7257328B2 (ja) | ベンゾフラン誘導体遊離塩基の結晶およびその製造方法 | |
| JP2017513915A5 (cg-RX-API-DMAC7.html) | ||
| JP2017527598A5 (cg-RX-API-DMAC7.html) | ||
| JP2013522316A5 (cg-RX-API-DMAC7.html) | ||
| JP2018510131A5 (cg-RX-API-DMAC7.html) |